OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Publication Date
Release Date
2020
(2)
2021
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Not available
S-EPMC7731769
|
biostudies-literature
Cite
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
Not available
S-EPMC8253801
|
biostudies-literature
Cite
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Not available
S-EPMC7027476
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
